Cover Image
Read Now

Minocycline for relapsing-remitting multiple sclerosis and clinically isolated syndrome a review of clinical effectiveness and guidelines

Bibliographic Details
Main Authors: Marchand, Dave K., Butcher, Robyn (Author)
Format: eBook
Language:English
Published: Ottawa CADTH 2019, September 16, 2019
Edition:Version: 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Treatment Outcome
Anti-bacterial Agents / Therapeutic Use
Multiple Sclerosis / Drug Therapy
Minocycline / Therapeutic Use
Practice Guidelines As Topic
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02230nam a2200301 u 4500
001 EB001999425
003 EBX01000000000000001162326
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
100 1 |a Marchand, Dave K. 
245 0 0 |a Minocycline for relapsing-remitting multiple sclerosis and clinically isolated syndrome  |h Elektronische Ressource  |b a review of clinical effectiveness and guidelines  |c authors, Dave K. Marchand, Robyn Butcher 
250 |a Version: 1.0 
260 |a Ottawa  |b CADTH  |c 2019, September 16, 2019 
300 |a 1 PDF file (18 pages)  |b illustration 
505 0 |a Both clinically isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS) are managed with a variety of pharmacotherapies, such as: corticosteroids, immunosuppressants, immunomodulators, and drugs targeted to particular symptoms. The goals of therapy in CIS are to delay the onset of additional relapses and progression to MS. Whereas, the goals of therapy in RRMS include the management of flare-ups, prevention of future exacerbations, management of ongoing signs and symptoms (e.g., muscle spasms, pain), and supportive care. Recently, the immunomodulating properties of minocycline, a tetracycline antibiotic, were discovered to impact neurological diseases in animal experiments. Further studies revealed the drug's anti-inflammatory and neuroprotective effects, making it a interesting prospect for MS treatment. The objective of the current report is to evaluate the clinical effectiveness and evidence based guidelines regarding the use of minocycline in CIS and RRMS. 
505 0 |a Includes bibliographical references 
653 |a Treatment Outcome 
653 |a Anti-Bacterial Agents / therapeutic use 
653 |a Multiple Sclerosis / drug therapy 
653 |a Minocycline / therapeutic use 
653 |a Practice Guidelines as Topic 
700 1 |a Butcher, Robyn  |e [author] 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK549544  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 

Similar Items